1. Jafari E, Pourakbari B, Asadi Karam MR, Azizian R, Modaresi MR, Mamishi S. The Burden of Antimicrobial‐Resistant Pseudomonas aeruginosa Isolates in Children With Cystic Fibrosis: Molecular Characterization and Genotyping Analysis. MicrobiologyOpen. 2026;15(1):e70217.

2. Dehvari A, Bameri Z, Asadi Karam MR, Kord E, Oloomi M, Shahraki Zahedani S, et al. Determination of Effective Prophylactic Responses of Truncated Flagellin Protein as a Vaccine Candidate Against Uropathogenic Escherichia coli. International Journal of Microbiology. 2026;2026(1):9663212.

3. Pirhajati R, Chiani M, Habibi M, Emami T, Shahrokhi N, Karam MRA. Successful prophylactic against Brucella melitensis using a vaccine candidate consisting of recombinant antigens OMP19 and L7/L12 loaded in a nanoliposomal adjuvant system in a mouse model. International Journal of Pharmaceutics. 2025:126372.

4 . Mohammadzadeh R, Habibi M, Asadi Karam MR. Evaluation of a bivalent vaccine composed of iron scavenger receptors PMI1426 and PMI1945 against Proteus mirabilis. Future Microbiology. 2025;20(11):723-33.

5 . Mirsharifi S, Habibi M, Rahimi T, Foroohi F, Karam MRA. Immunogenic Potential of a Multi-Peptide Vaccine Construct Against Uropathogenic Escherichia coli-Associated Urinary Tract Infection. Iranian Biomedical Journal. 2025;29(4):247.

6 . Moradkasani S, Esmaeili S, Asadi Karam MR, Mostafavi E, Shahbazi B, Salek Farrokhi A, et al. Development of a multi-epitope vaccine from outer membrane proteins and identification of novel drug targets against Francisella tularensis: An In Silico approach. Frontiers in Immunology. 2025;16:1479862.

7. Sabzi S, Habibi M, Badmasti F, Shahbazi S, Karam MRA, Farokhi M. Polydopamine-based nano adjuvant as a promising vaccine carrier induces significant immune responses against Acinetobacter baumannii-associated pneumonia. International Journal of Pharmaceutics. 2024;654:123961.

8. Shahbazi S, Badmasti F, Habibi M, Sabzi S, Goodarzi NN, Farokhi M, Karam MRA, et al. In silico and in vivo Investigations of the Immunoreactivity of Klebsiella pneumoniae OmpA Protein as a Vaccine Candidate. Iranian biomedical journal. 2024;28(4):156.

9. Kalantari H, Habibi M, Ferdousi A, Asadi Karam MR, Mohammadian T. Development of a multi-epitope vaccine candidate against Pseudomonas aeruginosa causing urinary tract infection and evaluation of its immunoreactivity in a rabbit model. Journal of Biomolecular Structure and Dynamics. 2024;42(12):6212-27.

10. Parvaei M, Habibi M, Shahbazi S, Babaluei M, Farokhi M, Karam MRA. Immunostimulatory chimeric protein encapsulated in gelatin nanoparticles elicits protective immunity against Pseudomonas aeruginosa respiratory tract infection. International Journal of Biological Macromolecules. 2024;277:133964

11. Shahbazi S, Habibi M, Badmasti F, Sabzi S, Farokhi M, Karam MRA. Design and fabrication of a vaccine candidate based on rOmpA from Klebsiella pneumoniae encapsulated in silk fibroin-sodium alginate nanoparticles against pneumonia infection. International Immunopharmacology. 2023;125:111171.

12. Sadeghi S, Katebi A, Ghalamzan M, Beram FM, Afshari S, Shariati FS, et al. Hyaluronic acid-based hydrogel loaded with berberine hydrochloride promotes MRSA-infected wound healing. Talanta. 2026:129406.

13. Sadri H, Shahrokhi N, Ebrahimi-Rad M, Mardani M, Sadeghi S, Pooya M. Synergistic antibacterial and antibiofilm activity of N-acetylcysteine combined with niosomal recombinant lysostaphin against MRSA Staphylococcus aureus. Journal of Drug Targeting. 2025:1-14.

14. Ghodsi R, Tahouri SKS, Amjad F, Nasiri MR, Toutounchi A, Salehi H, Sadeghi S, et al. Chitosan/Alginate@ Niosome-curcumin: high-performance wound dressing with enhanced antibacterial activity. Journal of Drug Delivery Science and Technology. 2025:107438.

15. Mansouri A, Farsani NK, Javanmard A, Eskandarisani M, Mohebbi S, Tajik M, Sadeghi S, et al. Combating antimicrobial resistance: In vitro and in vivo efficacy of berberine-loaded metal-organic frameworks with hyaluronic acid coating. International Journal of Biological Macromolecules. 2025;308:142253.

16. Joni HA, Esmaeili F, Landi B, Bayat E, Bakhshandeh H, Talebkhan Y, Sadeghi S, et al. Formulation, Characterization, and Potential Therapeutic Implications of Encapsulated Recombinant Alpha-luffin in Niosomes. Current Pharmaceutical Biotechnology. 2025;26(6):923-34.

17. Sadeghi S, Agharazi F, Hosseinzadeh SA, Mashayekhi M, Saffari Z, Shafiei M, et al. Gold nanoparticle conjugation enhances berberine's antibacterial activity against methicillin-resistant Staphylococcus aureus (MRSA). Talanta. 2024;268:125358.

18. Hanifian H, Shahrokhi N, Nateghpour M, Haghi AM, Mohebali M, Foroushani AR, et al. A new approach: using antisense oligonucleotides to target AMA1 gene in treatment of malaria. 2025.

19. Mood EH, Japoni-Nejad A, Karam MA, Pooya M, Bouzari S, Shahrokhi N. Evaluation of accessible regions of Escherichia coli fimH mRNA through computational prediction and experimental investigation. Iranian Journal of Microbiology. 2021;13(5):653.

20. Shahrokhi N. Expression of Type II Toxin/Antitoxin systems and ClpP protease of Methicillin-Resistant Staphylococcus aureus under stress condition. 2020.

21. Bouzari S, Shahrokhi N, Dashti A, Janani A-R, Jafari A. Construction and evaluation of chimeric heat-labile toxin B subunit and N-terminal (1–75) fragment of colonization factor antigen I gene of enterotoxigenic Escherichia coli. Annals of microbiology. 2010;60(2):255-61.

22. Pooya M, Saleh M, Abd A, Mazaheri H, Khosravi E, Abdollahi A, et al. Do phenotypic and genotypic characteristics of uropathogenic E. coli isolates differ in acute and recurrent phases of urinary tract infection? International Journal of Infectious Diseases. 2020;101:133.

23. Farzi N, Pourramezan Z, Attar FA, Mostaan S, Oloomi M. Sequence-subtype association of multi-drug-resistant diarrheagenic Escherichia coli. Iranian Journal of Microbiology. 2024;16(2):176.

24. Eybpoosh S, Mostaan S, Gouya MM, Masoumi-Asl H, Owlia P, Eshrati B, et al. Frequency of five Escherichia Coli pathotypes in Iranian adults and children with acute diarrhea. PLoS One. 2021;16(2):e0245470

25. Jafari E, Mostaan S, Bouzari S. Characterization of antimicrobial susceptibility, extended-spectrum β-lactamase genes and phylogenetic groups of enteropathogenic Escherichia coli isolated from patients with diarrhea. Osong Public Health and Research Perspectives. 2020;11(5):327.

26. Mostaan S, Ghasemzadeh A, Sardari S, Shokrgozar MA, Brujeni GN, Abolhassani M, et al. Pasteurella multocida vaccine candidates: A systematic review. Avicenna journal of medical biotechnology. 2020;12(3):140.

27. Mostaan S, Ghasemzadeh A, Ehsani P, Sardari S, Shokrgozar MA, Abolhassani M, et al. In silico analysis of Pasteurella multocida PlpE protein epitopes as novel subunit vaccine candidates. Iranian biomedical journal. 2020;25(1):41

28. Mostaan S, Ghasemzadeh A, Ehsani P, Sardari S, Shokrgozar MA, Abolhassani M, et al. Plpe epitopes of pasteurella multocida fusion protein as novel subunit vaccine candidates. Advanced Biomedical Research. 2020;9(1):43.

29. Behrouzi A, Vaziri F, Rahimi-Jamnani F, Afrough P, Rahbar M, Satarian F, et al. Vaccine candidates against nontypeable Haemophilus influenzae: a review. Iranian Biomedical Journal. 2017;21(2):69.

 30. Malekan M, Tabaraie B, Akhoundtabar L, Afrough P, Behrouzi A. Distribution of class I integron and smqnr resistance gene among Stenotrophomonas maltophilia isolated from clinical samples in Iran. Avicenna Journal of Medical Biotechnology. 2017;9(3):138.

31. Kalantar E, Kurd A, Kabir K, Afrogh P, Mohammadi S, Naseh MH. Extreme antibiotic resistant acinetobacter baumannii-related pneumonia in a regional hospital. 2016.

32. Afrough P, Behrouzi A, Davari M, Malekan M, Fateh A, Vaziri F, et al. Cloning and expression of porA gene as the first step of a vaccine candidate study against Neisseria meningitidis serogroup A infection. 2016.

33. Nia NZ, Pourmand MR, Afrough P. Comparison of hypervariable region (hvr) of meca gene in staphylococcus aureus isolated from nasal carriers and clinical samples. Jundishapur Journal of Microbiology. 2013;6(9):A1.

34, Mardaneh J, Poor SA, Afrugh P. Prevalence of Shigella species and antimicrobial resistance patterns of isolated strains from infected pediatrics in Tehran. Int J Entric Pathog. 2013;1(1):28-31

35. Bahloli M, Kafil HS, Roshani Asl P, Rashidi N, Moaddab SR. Evaluation of Antimicrobial Susceptibility in Extended-Spectrum β-Lactamase Producing Escherichia coli Isolates From Patients in Northwest Iran. Avicenna Journal of Clinical Microbiology and Infection. 2024;11(1):22-7.

36. Ghaemi A, Roshani Asl P, Zargaran H, Ahmadi D, Hashimi AA, Abdolalipour E, et al. Recombinant COVID-19 vaccine based on recombinant RBD/Nucleoprotein and saponin adjuvant induces long-lasting neutralizing antibodies and cellular immunity. Frontiers in immunology. 2022;13:974364.

37. Gharavi MJ, Zarei J, Roshani AP, Yazdanyar Z, Sharif M, Rashidi N. Determination of Helicobacter pylori infection prevalence by non-invasive methods. 2022.

38. Gharavi MJ, Zarei J, Roshani-Asl P, Yazdanyar Z, Sharif M, Rashidi N. Comprehensive study of antimicrobial susceptibility pattern and extended spectrum beta-lactamase (ESBL) prevalence in bacteria isolated from urine samples. Scientific reports. 2021;11(1):578.

39. Kazemiha VM, Azari S, Habibi-Anbouhi M, Amanzadeh A, Bonakdar S, Shokrgozar MA, et al. Effectiveness of Plasmocure™ in elimination of mycoplasma species from contaminated cell cultures: a comparative study versus other antibiotics. Cell Journal (Yakhteh). 2019;21(2):143.

40. Amanzadeh A, Molla-Kazemiha V, Samani S, Habibi-Anbouhi M, Azadmanesh K, Abolhassani M, et al. New synergistic combinations of differentiation-inducing agents in the treatment of acute promyelocytic leukemia cells. Leukemia Research. 2018;68:98-104.

41. Amanzadeh A, Molla-kazemiha V, Habibi-Anbouhi M, Azadmanesh K, Mousavi SA, Abolhassani M, et al. Induction of programmed cell death by “Retinoic acid, Formylindolo (3, 2-b) carbazole”-enhanced monoclonal antibody against CD44 in acute promyelocytic leukemia cells patients. New Cellular and Molecular Biotechnology Journal. 2018;8(31):9-19.

42. Amanzadeh A, Heidarnejad F, Abdollahpour-Alitappeh M, Molla-Kazemiha V, Yari S, Hadizadeh-Tasbiti A, et al. Development of high-affinity monoclonal antibody using CD44 overexpressed cells as a candidate for targeted immunotherapy and diagnosis of acute myeloid leukemia. Human antibodies. 2018;26(1):7-15.